Drug Trial Radar · NCT07033026
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Jun 25, 2025
Primary completion
Apr 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- NGM Biopharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Conditions
- Colorectal Cancer
- CRC (Colorectal Cancer)
- Cancer Cachexia
Interventions
NGM120 Q4WDrug
NGM120 given subcutaneously every 4 weeks
NGM120 Q8WDrug
NGM120 given subcutaneously every 8 weeks
Placebo givenDrug
Placebo given subcutaneously every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in body weight at Week 12Time frame: 12 Weeks
- Treatment-emergent adverse events (TEAEs) characterized by type, frequency, severity, timing, seriousness, and relationship to study drugTime frame: 44 Weeks
Locations
28 sites in 4 countries. Site status is shown where the registry gives one.
NGM Clinical Study Site
Los Angeles, California · Recruiting
NGM Clinical Study Site
Los Angeles, California · Recruiting
NGM Clinical Study Site
Santa Rosa, California · Recruiting
NGM Clinical Study Site
Margate, Florida · Recruiting
NGM Clinical Study Site
Baltimore, Maryland · Recruiting
NGM Clinical Study Site
New York, New York · Recruiting
NGM Clinical Study Site
Toledo, Ohio · Recruiting
NGM Clinical Study Site
Youngstown, Ohio · Recruiting
NGM Clinical Study Site
Dallas, Texas · Recruiting
NGM Clinical Study Site
Kingwood, Texas · Withdrawn
NGM Clinical Study Site
Laredo, Texas · Recruiting
NGM Clinical Study Site
Richmond, Virginia · Recruiting
NGM Clinical Study Site
Appleton, Wisconsin · Recruiting
NGM Clinical Study Site
Tbilisi, Georgia · Recruiting
NGM Clinical Study Site
Tbilisi, Georgia · Recruiting
NGM Clinical Study Site
Tbilisi, Georgia · Recruiting
NGM Clinical Study Site
Tbilisi, Georgia · Recruiting
NGM Clinical Study Site
Tbilisi, Georgia · Recruiting
NGM Clinical Study Site
Goyang, South Korea · Recruiting
NGM Clinical Study Site
Goyang, South Korea · Recruiting
NGM Clinical Study Site
Incheon, South Korea · Recruiting
NGM Clinical Study Site
Seoul, South Korea · Recruiting
NGM Clinical Study Site
Seoul, South Korea · Recruiting
NGM Clinical Study Site
Seoul, South Korea · Recruiting
NGM Clinical Study Site
Suwon, South Korea · Recruiting
NGM Clinical Study Site
Taichung, Taiwan · Recruiting
NGM Clinical Study Site
Taipei, Taiwan · Recruiting
NGM Clinical Study Site
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.